Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ryvu TherapeuticsLTS:0RKT 66 Days Inventory is 29.49 as of Mar. 2026, which is 20% below its 10-year median of 37.09. GuruFocus rates LTS:0RKT with a GF Score™ of 66/100 and a GF Value™ of zł86.63. The stock has 3 warning signs investors should review. Among 638 Biotechnology companies, Ryvu Therapeutics ranks better than 93.1% on this metric.
The historical rank and industry rank for Ryvu Therapeutics's Days Inventory or its related term are showing as below:
LTS:0RKT'
s Days Inventory Range Over the Past 10 Years
Min: 7.51 Med: 37.09 Max: 67.93
Current: 24.5
During the past 13 years, Ryvu Therapeutics's highest Days Inventory was 67.93. The lowest was 7.51. And the median was 37.09.
LTS:0RKT's Days Inventory is ranked better than 93.1% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs LTS:0RKT: 24.50
Ryvu Therapeutics's Days Inventory
declined
from Mar. 2025 (29.78) to Mar. 2026 (29.49).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Ryvu Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 was 3.09.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ryvu Therapeutics's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.08.
Ryvu Therapeutics (LTS:0RKT) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Ryvu Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ryvu Therapeutics's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Ryvu Therapeutics Days Inventory Related Terms
Ryvu Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Ryvu Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RKT vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Ryvu Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ryvu Therapeutics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Ryvu Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ryvu Therapeutics (LTS:0RKT) has a Days Inventory of 29.49 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Ryvu Therapeutics and its competitors. This is 20% below median its historical median of 37.09. Over the past decade, Ryvu Therapeutics' Days Inventory has ranged from 7.51 to 67.93. According to the industry distribution chart, Ryvu Therapeutics ranks #44 out of 638 companies in the Biotechnology industry, placing it in the top 6.9%.
Is Ryvu Therapeutics' Days Inventory too high?
Ryvu Therapeutics' current Days Inventory of 29.49 is 20% below median its 10-year median of 37.09. Over the past 10 years, this metric has ranged from a low of 7.51 to a high of 67.93. The Biotechnology industry median Days Inventory is 183.20. Ryvu Therapeutics' value of 29.49 is 83.9% below this industry median. Based on the distribution chart, Ryvu Therapeutics ranks #44 out of 638 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ryvu Therapeutics has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ryvu Therapeutics ranks #44 out of 638 companies for Days Inventory. This places Ryvu Therapeutics in the top 7% of its industry — outperforming the majority of peers. The industry median Days Inventory is 183.20. Ryvu Therapeutics' value of 29.49 is 83.9% below this benchmark. Historically, Ryvu Therapeutics' own Days Inventory has ranged from 7.51 to 67.93 over the past decade. While the company's 10-year median is 37.09 vs. the industry median of 183.20, Ryvu Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ryvu Therapeutics's current Days Inventory of 29.49 is 83.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Ryvu Therapeutics and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ryvu Therapeutics's current Days Inventory is 29.49, which is 20% below median its own 10-year median of 37.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Ryvu Therapeutics (LTS:0RKT) has a current Days Inventory of 29.49. The stock's GF Value™ is zł86.63, compared to a current price of zł30.25 — trading 65.1% below its estimated fair value. The current Days Inventory is 29.49, which is 20% below median its 10-year median of 37.09 and 83.9% below the Biotechnology industry median of 183.20. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Ryvu Therapeutics (LTS:0RKT), the current Days Inventory is 29.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ryvu Therapeutics (LTS:0RKT) Overvalued in 2026?
Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued.
The current stock price of zł30.25 is trading 65.1% below its estimated GF Value™ of zł86.63.
Key valuation signals for LTS:0RKT:
Days Inventory: 29.49 (20% below median its 10-year median of 37.09)
GF Value™: zł86.63 vs. price of zł30.25 (65.1% below fair value)
Industry Position: 83.9% below the Biotechnology median (#44 of 638)
No single metric tells the full story. See the LTS:0RKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score
Get the complete analysis for LTS:0RKT
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RKT has been successfully added to your 
